STOCKHOLM, SWEDEN – September 2, 2020. Karolinska Growth (Nasdaq Stockholm: KDEV) declares that its portfolio firm Umecrine Cognition will current the outcomes from its not too long ago performed medical part 2a research of the drug candidate golexanonole, that’s in medical improvement for hepatic encephalopathy. The outcomes shall be offered at The Liver Assembly Digital Expertise™ on November 13–16, 2020.
Umecrine Cognition’s drug candidate golexanolone, a novel orally-active GABAA receptor modulating steroid antagonist, is concentrating on the debilitating symtoms of hepatic encephalopathy (HE). Following a not too long ago performed medical part 2a research, the corporate will current the outcomes at The Liver Assembly, one the world’s largest conferences within the subject of hepatic medication. Previous to the assembly, Umecrine Cognition’s scientific summary of the research outcomes has been ranked within the high 10 p.c, and chosen as a “Poster of Distinction”, and can obtain particular recognition by AALSD.
“We’re glad that the outcomes from Umecrine Cognition’s medical research are obtained with such curiosity and that the corporate is being seen as an essential actor at one of many largest conferences within the subject”, says Viktor Drvota, CEO Karolinska Growth.
For additional info, please contact:
Viktor Drvota, CEO, Karolinska Growth AB
Cellphone: +46 73 982 52 02, e-mail: [email protected]
About Karolinska Growth AB
Karolinska Growth AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences funding firm. The corporate focuses on figuring out breakthrough medical improvements within the Nordic area which are developed by entrepreneurs and management groups. The Firm invests within the creation and development of firms that advance these property into business merchandise which are designed to make a distinction to sufferers’ lives whereas offering a beautiful return on funding to shareholders.
Karolinska Growth has entry to world-class medical improvements on the Karolinska Institutet and different main universities and analysis institutes within the Nordic area. The Firm goals to construct firms round scientists who’re leaders of their fields, supported by skilled administration groups and advisers, and co-funded by specialist worldwide buyers, to supply the best likelihood of success.
Karolinska Growth has a portfolio of ten firms concentrating on alternatives in modern therapy for life-threatening or severe debilitating ailments.
The Firm is led by an entrepreneurial group of funding professionals with a confirmed monitor file as firm builders and with entry to a powerful world community.
For extra info, please go to www.karolinskadevelopment.com